J. Blue

Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial.

J. Tardif, J. Grégoire, P. L'Allier, 2002, American heart journal.

Effects of the Acyl Coenzyme A:Cholesterol Acyltransferase Inhibitor Avasimibe on Human Atherosclerotic Lesions

Fernando Alfonso, Jean-Claude Tardif, Jean Grégoire, 2004, Circulation.

Efficacy Measures: Surrogates or Clinical Outcomes?

W. Colburn, J. Blue, 1996, Journal of clinical pharmacology.

Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients.

A. Collins, S. Swan, W. Colburn, 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Monitoring a clinical trial conducted under the Food and Drug Administration regulations allowing a waiver of prospective informed consent: the diaspirin cross-linked hemoglobin traumatic hemorrhagic shock efficacy trial.

D. Berry, R. Bechhofer, R. Lewis, 2001, Annals of emergency medicine.

The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease

M. Criqui, J. Regensteiner, W. Hiatt, 2004, Vascular medicine.

Diaspirin-Crosslinked Hemoglobin Reduces Blood Transfusion in Noncardiac Surgery: A Multicenter, Randomized, Controlled, Double-Blinded Trial

E. Mascha, J. Eidt, A. Novick, 2003, Anesthesia and analgesia.